Novocure Reports Second Quarter 2026 Financial Results
Business Wire•23/07/2026•07:00 ET
0
Whiz Insights
Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications
CE Mark received for Optune Pax®( )for the treatment of locally advanced pancreatic cancer, Germany first market to launch in EU
Get started
Create a free account to read the full story.